Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NovImmune, a Swiss drug maker, has started a Proof-of-Concept (PoC) study to evaluate NI-0801 in patients with PBC.
Subscribe to our email newsletter
The results from two previous Phase I trial demonstrated that the drug was safe and well tolerated when administered in healthy volunteers.
NI-0801 is a fully human monoclonal antibody that neutrilizes CXCL10/Interferon-gamma-inducible protein-10 (IP-10) chemokine.
Principal investigator of the PoC study David Adams said the therapeutic approach of neutralizing CXCL10/IP-10 with NI-0801 will potentially offer, for the first time, great benefits to the large and therapeutically ill-served PBC patient population.